niftify.in

Business Line

Stock to buy today: Alembic Ltd (₹163)

Book profits at ₹175

The Economic Times

Alembic Pharma gets USFDA nod for generic product

Alembic Pharmaceuticals has received approval from the USFDA to market Albendazole Tablets USP (200 mg), a generic drug for treating infections caused by worms. The tablets are equivalent to Impax Laboratories' Albenza and are used for conditions like parenchymal neurocysticercosis and cystic hydatid disease. Alembic Pharma shares rose 2.79% on Thursday.

Business Standard

Alembic Pharma shares rise after USFDA drug approval; check details here

Shares of Alembic Pharmaceuticals soared up to 4.13 per cent at Rs 1,135 per share on the BSE

The Economic Times

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has been granted final approval from the USFDA for its generic Betamethasone Valerate Foam, intended to treat moderate-to-severe psoriasis of the scalp. This medication is equivalent to Luxiq Foam by Norvium Bioscience. Alembic’s shares ended 0.97% lower at Rs 1,089.90 on the BSE.

Business Standard

Here's why Alembic Pharma stock skyrocketed 12% on August 26; details here

The surge in Alembic Pharma share price came after the company announced that it has received US Food & Drug Administration (USFDA) final approval for Betamethasone Valerate Foam, 0.12 per cent.

Business Standard

Alembic Pharma gets USFDA nod for Betamethasone Valerate Foam

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam.

Business Standard

Alembic Pharmaceuticals receives USFDA approval for Betamethasone Valerate Foam

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium).

The Economic Times

Alembic gets USFDA nod for generic medication

Alembic Pharmaceuticals announced approval from the USFDA to market Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis prophylaxis, equivalent to Pradaxa Capsules. The company now has 211 ANDA approvals. Shares closed 3.17% lower at Rs 1,076 on the BSE.

Business Line

FDA approves Alembic’s psoriasis drug

Alembic’s psoriasis drug Acitretin has $21-million market size

The Economic Times

Alembic Pharma gets USFDA nod for generic Bromfenac ophthalmic solution

Alembic Pharmaceuticals Ltd has obtained final approval from the US FDA for its generic Bromfenac ophthalmic solution, used to treat postoperative inflammation and pain after cataract surgery. The approved product is equivalent to Prolensa Ophthalmic Solution, with an estimated market size of USD 168 million.

Business Standard

Alembic receives USFDA approval for Bromfenac Ophthalmic Solution

Bromfenac Ophthalmic Solution 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

The Economic Times

Alembic Pharma gets USFDA nod for Dabigatran Etexilate capsules

Alembic Pharmaceuticals Ltd received final approval from the US health regulator for generic Dabigatran Etexilate capsules 75 mg and 150 mg to reduce stroke and blood clots in adults with a specific medical condition.

The Economic Times

Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedema

The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) for Icatibant injection of strengths 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe, Alembic Pharmaceuticals said in a regulatory filing.